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Abstract
Background: During the stages of the development of a potent drug candidate compounds can
fail for several reasons. One of them, the efficacy of a candidate, can be estimated in silico if an
appropriate ordinary differential equation model of the affected pathway is available. With such a
model at hand it is also possible to detect reactions having a large effect on a certain variable such
as a substance concentration.
Results: We show an algorithm that systematically tests the influence of activators and inhibitors
of different type and strength acting at different positions in the network. The effect on a quantity
to be selected (e.g. a steady state flux or concentration) is calculated. Moreover, combinations of
two inhibitors or one inhibitor and one activator targeting different network positions are analysed.
Furthermore, we present TIde (Target Identification), an open source, platform independent tool
to investigate ordinary differential equation models in the common systems biology markup
language format. It automatically assigns the respectively altered kinetics to the inhibited or
activated reactions, performs the necessary calculations, and provides a graphical output of the
analysis results. For illustration, TIde is used to detect optimal inhibitor positions in simple
branched networks, a signalling pathway, and a well studied model of glycolysis in Trypanosoma
brucei.
Conclusion: Using TIde, we show in the branched models under which conditions inhibitions in
a certain pathway can affect a molecule concentrations in a different. In the signalling pathway we
illuminate which inhibitions have an effect on the signalling characteristics of the last active kinase.
Finally, we compare our set of best targets in the glycolysis model with a similar analysis showing
the applicability of our tool.
Background
In the current pharmaceutic development new drugs are
often found by screening a library of small molecular enti-
ties (SME) against so-called 'blockbuster targets' which are
supposed to play a relevant role in the onset of a certain
disease. The development of drugs for new targets is in
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most cases less interesting for a pharmaceutical company
due to the fact that the research is more expensive, they
fail pre-clinical trials more often and are in most cases
financially less successful [1,2]. In order to increase the
productivity of 'Research and Development' (R&D) when
focussing on novel targets a possible way is to identify
candidates which are likely to fail trials earlier in the drug
development process [3].
One problem that drugs against novel targets can cause is
their possible lack of efficacy. During the development,
possible targets are validated via knock-out experiments
which work in a totally different way than medication
with competitive inhibitors against the corresponding
enzymes. While in the first case the flux through a certain
pathway can be completely shut down, in the second case
it will only be partially decreased which the system can
overcome, e.g. by substrate accumulation or feedback reg-
ulation. Therefore quantitative modelling should be
incorporated into drug research.
A systematic approach to the identification of possible
drug targets in a reaction network renders possible with
the established tools and methods used in systems biol-
ogy. Over the last years more and more mathematical
models for chemical reaction networks have proven to be
successful in predicting an microorganism's response to
changes in its environment and to perturbations in its
gene expression [4-6]. These models are being collected in
steadily growing databases like BioModels [7] or JWS
online [8]. A promising approach to a systematic drug
design is to simulate possible inhibitors to any reaction in
a given network and to quantify their effects on a given
observable. This observable can be defined as any inner
variable of the system, e.g. the concentration of a sub-
stance or the flux through a certain reaction which is
altered in the pathological state. For a more complex anal-
ysis this observable can also be defined as any function of
these variables. From the time course of the observable,
several characteristics can be extracted for later compari-
son. These include the steady state values, which are inter-
esting for models of metabolic pathways, and several
characteristics, which are relevant to signalling cascade
models, namely the integrated concentration, the charac-
teristic time, the signal duration, and the signal amplitude
as described in [9,10]. Given this information from sev-
eral simulations using different inhibition targets, types,
and inhibitor concentrations, one can select favourable
modification scenarios. "Favourable" means here that in a
certain scenario a given observable reaches a desired value
while the system is perturbed by few inhibitors in small
concentrations.
Such a kind of analysis has already been applied manually
to different kinds of small example models [11-14] and
larger, biologically relevant models [15,16].
Other approaches to determine modified enzyme activi-
ties in order to achieve a certain change in a systems
behaviour already exist (e.g. [17] and [18]), but none of
them exhaustively searches the space of possible drug
combinations, tries to minimise the amount of used
inhibitor, or explicitly models different types of modifica-
tion kinetics. A broad overview on similar methods can be
found in [19].
Implementation
In order to simplify the error prone process of inhibiting
or activating (from now on referred to as modifying) sin-
gle reactions and investigating the results in a given ODE
model, we have developed a platform independent tool
written in Python [20] which performs this analysis auto-
matically. The tool called TIde (Target Identification,
http://sysbio.molgen.mpg.de/tide) works in three steps
(as shown in Figure 1). First, it imports an ODE model
given in the Systems Biology Markup Language (SBML)
format [21] making use of libSBML [22]. The reaction
kinetics in the imported model are identified by compar-
ing their formulas to kinetic formulas from an internal
database. This database is based on kinetics from the Sys-
tems Biology Ontology (SBO) [23] and was later extended
manually. Second, it replaces individual reaction kinetics
or combinations thereof by corresponding modifier kinet-
ics and simulates the altered models for different modifier
concentrations. Finally, it systematically compares the
results of these simulations in order to determine single or
multiple optimal drug targets.
In the following, these three steps of the tool's functional-
ity will be explained.
Overview on the simulation steps performed in the algo- rithm Figure 1
Overview on the simulation steps performed in the 
algorithm.BMC Bioinformatics 2009, 10:344 http://www.biomedcentral.com/1471-2105/10/344
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Identification of reaction kinetics
Starting from an SBML model, TIde is supposed to simu-
late the effects of different modifications of single reac-
tions and combinations thereof. Therefore, the first step of
the tool is the identification of the present kinetic formu-
las for each reaction by numerically comparing them to
known kinetic types collected in an internal database. The
identity of two formulas is judged by testing all possible
parameter matchings of those formulas, repeatedly replac-
ing the parameters by random values, and checking
whether the results are similar except for numerical inac-
curacy. Using the information about the present kinetics,
the database can be searched for known modifier formu-
las. The identification of the kinetic parameters makes it
possible to automatically replace a kinetic by a formula
representing a certain kind of modification mechanism
acting on the corresponding enzyme.
Replacing reaction kinetics by corresponding 
modifications
Then, a set of new models is created in which systemati-
cally every reaction is replaced by a modification. During
this step up to five new models per reaction can be created
since four types of modifications are known to the data-
base. These types are competitive, uncompetitive, and
noncompetitive inhibition and nonessential activation.
Additionally, a competitive inhibition for cofactors is
available.
Unknown formulas (vi(S,p) with reaction velocity vi which
is dependent on substance concentrations S and parame-
ters p) will automatically be added to the internal data-
base. Also a standard noncompetitive inhibition
( , with inhibitor concen-
tration I and its dissociation constant Ki) and a standard
nonessential activation
( ) with activator con-
centration A and its dissociation constant Ka) will be cre-
ated. Because of that the number of new models created
during this step will be at least twice as large as the
number of reactions included in the original model.
In a step including user interaction, also different compet-
itive and uncompetitive inhibitions can be included into
the internal database. The user interaction involves the
identification of Km  values for substrates of reactions
which are supposed to be inhibited. For the selected Km
values new competitive inhibitions are created by multi-
plying the original Km by a factor  . Uncompetitive
inhibitions are created similarly by dividing the Km and
Vmax values by the same factor. For SBML models includ-
ing complex kinetics this step should be taken as the data-
base can not cover all possible types of kinetic formulas.
TIde can also be used to check combinations of modifiers.
These modifications do not need to be of the same type,
but they have to affect different reactions.
Comparing results of different modifications
In order to examine the effects of different modifications
the user has to define the objective function which is to be
maximized or minimized. This function can be an arbi-
trary formula containing substance concentrations or
fluxes or a combination of them if the steady values are of
interest (e.g.  ). In case that sig-
nalling characteristics should be evaluated the objective
function can in the current implementation only be a sin-
gle compound concentration.
The effects of different inhibitor concentrations can be
evaluated by either testing several distinct effective con-
centrations (  or  ) in separate simulations or one
simulation of a continuous titration of the inhibitor.
Optionally these titrations can also be performed until the
objective function has reached a certain value.
After the simulations of the new models have been per-
formed making use of either the SciPy [24] library, the
SBML Ode Solver library [25], or Copasi [26], the absolute
differences between the original value of the objective
function and its new values in the modification scenarios
are calculated and displayed.
Results and Discussion
We analysed four different models with the TIde tool
(using Copasi for simulation) as discussed in the follow-
ing. The first two models were simple metabolic pathways
including a branch, the third was a simple signalling cas-
cade, and the fourth one was a biologically relevant exam-
ple of aerobic metabolism in Trypanosoma brucei [6].
Prebranch model
The first two models (shown in Figure 2, left and middle)
were extensions of a simple linear reaction chain by a
small pathway bringing "biomass" either towards or away
from the center of the chain. By this extension the path-
way is divided into three subpathways. In the models we
chose the concentration of species_7 as an objective func-
tion for minimization. With these models we did not only
want to infer optimal modification targets in branched
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Graphs from the prebranch, the postbranch, and the signalling cascade model Figure 2
Graphs from the prebranch, the postbranch, and the signalling cascade model. The first two models contain only 
reversible Michaelis Menten kinetics with most parameters (Vr (maximum backward velocity), Kms (binding constant of the sub-
strate), Kmr (binding constant of the product)) set to 1 and all Vf (maximum forward velocity) values set to 10. The concentra-
tions of the topmost substances in these models (species_1 and in the prebranch species_4) are set to 1 and kept fixed and the 
concentrations of the bottommost ones are kept at 0. In both cases the steady state concentration of species_7 is to be mini-
mized. In the third model the concentrations of the activated receptor (Ra) and the inactive kinases (X, Y, and Z) are set to 1 
while all others are set to 0. The phosphorylation steps (reactions 2, 4, and 6) occur at a rate of  , the dephos-
phorylation steps (reactions 3, 5, and 7) at  , and the receptor inactivation (reaction 1) at v = 0.1 * Ra. This figure has 
been produced with the help of sbml2dot [28].
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systems but also test whether it was possible (and favour-
able) to target enzymes in a certain pathway when a sub-
stance which is to be affected is in a different one. The
result of the search for optimal drug targets depended on
the parameters in the model. Nevertheless, in the scope of
this article only the results for the most likely parameter
set (see Figure 2) can be discussed in detail.
As shown in the upper part of Figure 3, inhibiting a single
reaction (5 or 6) in the same pathway as species_7 was
more effective than inhibiting two reactions anywhere
else. Because of the large equilibrium constants, which
make "early" reactions in a linear pathway better targets,
also combined inhibitions of reactions 1 and 5 or 3 and 5
have a quite strong effect. An inhibition of reactions 1 and
3 had in this case a larger effect than inhibiting only reac-
tion 5. Still this combined inhibition in distant pathways
was only slightly more advantageous than a single inhibi-
tion in the same pathway as the observed species. To the
authors' surprise, at equilibrium constants equal to one
(data not shown) it seemed to be quite ineffective to use
modifications in other pathways in order to alter the con-
centration of a substance in a certain one, even if all reac-
tions leading towards the observed substance were
targeted. Nevertheless, a metabolic pathway in which the
equilibrium constants are not bigger than one is very
unlikely because it would not degrade the initial sub-
stance without the supply of external energy.
Postbranch model
The postbranch model (see Figure 2, middle) was a slight
modification of the previous model in which the third
pathway was not directed to carry biomass into the center
of the model but away from it. Here the idea was to study
whether this third pathway could be activated in order to
compete for biomass from the pathway including
species_7.
As shown in Figure 4, in this model it was most effective
to inhibit reactions 1 and 5. Because of the large equilib-
rium constants the combination of inhibitions at reac-
tions 1 and 2, which are optimal targets at constants equal
to one (data not shown), was a little less effective while
inhibiting reaction 1 and activating reaction 3 was a pos-
sible alternative. So, an activation of a competing pathway
could not outperform other inhibitions but it made a
good addition to them.
Simple signalling cascade
The third model was a signalling cascade (see Figure 2,
right). Here, we observed the effects of single modifica-
tions of the phosphorylation and dephosphorylation
steps on the last activated kinase. Since the active receptor
was constantly degraded, the steady state concentration of
the last activated kinase was always zero. Therefore, we
investigated more suitable characteristics of the dynamic
behaviour (see Table 1). The integrated concentration, the
Effects of different modifications on the prebranch model Figure 3
Effects of different modifications on the prebranch model. The axes of the tables specify the reaction which is modi-
fied, the modification type and the effective concentration of the modifier (  or  ). Descriptions have been abbreviated in 
order to reduce the table size; r3in0.1 means that reaction_3 is noncompetitively inhibited with an effective inhibitor concen-
tration of 0.1. Other possible types of modification are competitive inhibition (c), cofactor competitive inhibition (k), uncom-
petitve inhibition (u), or nonessential activation (a). Values on the diagonal describe the absolute change in the steady state 
concentration of species_7 when only one reaction is modified while values apart from the diagonal describe the change result-
ing from modifying two reactions at once. Near diagonal entries are blank because one single reaction is not modified twice.
1
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characteristic time, the signal amplitude and the duration
were influenced positively by the phosphorylation reac-
tions, which means that an activation of the reaction
increased the value of the signal characteristics. In the case
of the dephosphorylation reactions the effect was adverse.
In most cases the first reactions had a larger effect than the
latter ones although some characteristics seemed to differ
from that rule, e.g. the signal amplitude which could not
be increased beyond a certain value in this model.
Model of Trypanosoma glycolysis
Finally, in order to demonstrate the applicability of our
tool, we investigated possible modification patterns in an
updated model of the aerobic metabolism in Trypanosoma
brucei  [27] (BioModels BIOMD0000000211). For an
older version of this model a similar analysis has already
been performed manually [15]. The updated model con-
tains new and more detailed information on enzyme
kinetics under more realistic conditions and therefore
these new results could lead to more promising drug tar-
gets against sleeping sickness. We have chosen the steady
state flux through the upper glycolysis as the variable to be
minimized by different modifications.
Since the data produced by TIde was too extensive to dis-
play in paperform, only specific results could be shown in
Figure 5 and Tables 2 and 3. The favourability of inhibi-
tion target and kinetic type over others depended on the
degree to which the flux through the glycolysis should be
reduced in the parasite (see Figure 5). Therefore, we
focussed on inhibitor concentrations decreasing the flux
by 50% which was supposed to be sufficient to kill the
parasite. As proposed earlier [15], the most promising tar-
get was the glucose transporter (GT). The best targets
inside the glycolysis to achieve this goal were the phos-
phoglycerate mutase (PGM), the glyceraldehyde-3 phos-
phate dehydrogenase (GAPDH), the glycorol-3-
phosphate dehydrogenase (GPDH), the enolase (ENO),
and the fructose bisphosphate aldolase (ALD) in this
order. As depicted in Table 1, also in this group the quality
Same analysis of the postbranch model as done in Figure 3 Figure 4
Same analysis of the postbranch model as done in Figure 3.
Table 1: Relative changes of the signalling characteristics of "Zp" in the small cascade model. 
Target Amplitude Integrated signal στ
reaction_1 -0.02738 44.05890 14.57600 23.23040
reaction_2 -0.03430 -7.29018 -1.94723 -3.11361
reaction_3 0.04522 15.52320 4.26640 7.72552
reaction_4 -0.02467 -6.55773 -1.81591 -2.67058
reaction_5 0.02314 14.16874 4.16209 7.20750
reaction_6 -0.05883 -7.17961 -1.63696 -2.08881
reaction_7 -0.01467 10.28007 3.47335 5.24139
reference 1.57415 59.36095 18.85494 32.83275
The values in the table depict the relative changes of the characteristics after noncompetitive inhibition of a certain reaction by 50% compared to 
the reference state.BMC Bioinformatics 2009, 10:344 http://www.biomedcentral.com/1471-2105/10/344
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of a target depended on the type of inhibition. In the case
that only competitive inhibitors would be available the
GAPDH made an equally potent target as the GT. Earlier
results favoured the targets ALD, GAPDH, phosphoglycer-
ate kinase (PGK), and GPDH in this order besides the GT.
These findings do not differ that much from the current
results except for the PGK. This difference can be
explained by different enzyme kinetics, the fact that ENO
was not included as a single reaction in the old model,
and a slightly different analysis. 
Another topic we wanted to investigate were synergisms
and antagonisms of dual inhibitions in this model. The
strongest of them are shown in Table 3. As already known,
a strong synergism exists between the glycerol 3 phos-
phate oxidase (GPO) and the glycerol kinase (GK) but
also other combinations yielded interesting results. A
competitive inhibition of the triosephosphate isomerase
gave a strong synergism together with a competitive inhi-
bition for the cofactors for the phosphofructokinase
(PFK), with inhibitions of GK, and with an activation of
GPO. Strong antagonistic effects occurred between an acti-
vation of the hexokinase or the glucose transporter and
competitive (also for cofactors) inhibitions of the phos-
phoglycerate kinase and PFK. 
Conclusion
We have introduced an algorithm to systematically test
the effect of modifications or modifier combinations
depending their target and type as well as TIde, an imple-
mentation working on ODE models in the SBML format.
This process can be understood as an extension of meta-
bolic control analysis to multiple and strong perturba-
tions in an ODE model. Although TIde seems a bit
difficult to use in the first place needing a reliable ODE
model, being a command line tool, and having a limited
kinetic database the tool still has many advantages. Since
TIde is not platform dependend it can be run on any kind
of server making it possible to analyse even large models,
due to the extendible kinetic database it can be applied to
any ODE model, and because of the flexible objective
function it can be used for many different purposes. Fur-
thermore, we have tested our tool with a new version of
the glycolysis in Trypanosoma brucei. Our results are except
for some explainable changes in good agreement with
older findings proving the applicability of TIde.
Given a reliable ODE model and the information our tool
provides, the process of determining possible drugs is
more directed into efficacy of the candidates in pre-clini-
cal studies. Inclusion of this analysis will increase the
Simulated titration of the modifier in the Trypanosoma  model Figure 5
Simulated titration of the modifier in the Trypano-
soma model. Depicted is the change in the objective func-
tion, which is the steady state flux through the upper 
glycolysis (reference flux ≈ 90). The first diagram depicts the 
effect of noncompetitive inhibitions in different positions in 
the network. In the second diagramm, effects of different 
inhibition types on the hexokinase are shown.
Table 2: Effective inhibitor concentrations necessary to kill Trypanosoma brucei. 
noncompetitive uncompetitive competitive
Glucose transport 1.09 1.27 6.13
Phosphoglycerate mutase 1.81 1.81 > 10000
Glyceraldehyde-3-p. dehydr. 2.89 5.32 6.17
Glycerol-3-p. dehydr. 3.79 3.88 253
Enolase 6.4 6.4 > 10000
Aldolase 8.14 8.36 319
Shown are the concentrations required to reduce the flux through the upper glycolysis by 50% for different inhibition types and targets.BMC Bioinformatics 2009, 10:344 http://www.biomedcentral.com/1471-2105/10/344
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probability of a candidate to become a potent drug, and
decrease the cost of the development of 'new target' drugs.
This fact will hopefully draw the attention of the pharma-
ceutical industry towards the results produced by systems
biology. Since this research area is still growing more and
more ODE models, which are a necessary input to our
method, will become available.
In the future we plan to extend our tool to handle con-
straints which have to be fulfilled during simulation. The
idea behind this is that certain modifications and effective
modifier concentrations could lead to the death of the
simulated organism (e.g. if the ATP concentration drops
below a certain level). Such lethal modifications should
be considered in order to identify possible side effects of
the potential drug.
Availability and requirements
￿ Project name: TIde
￿ Project home page: http://sysbio.molgen.mpg.de/
tide/
￿ Operating systems: Cross platform
￿ Programming language: Python, C
￿ Other requirements: Python 2.5 or higher, SciPy 0.5
or higher, NumPy 1.1 or higher, PyX 0.9 or higher,
semanticSBML 1.0 or higher, libSBML 3.3
￿ License: GNU GPL
￿ Any restrictions to use by non-academics: None
Furthermore, we have attached a walkthrough for our tool
(see Additional file 1), its source code (see Additional file
2), and a Windows installer for the required tools and
libraries (see Additional file 3) to the article.
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Table 3: Strongest synergisms and antagonisms of combined modification in the Trypanosoma model.
Modification 1 Modification 2 Effect 1 Effect 2 Combined effect
GPO c/n/u GK c/k/n/u ≈ -1.2 ≈ -0.07 ≈ -84
PFK k TPI c -0.026 -1.48 -90
PGK k PGM c -0.13 -0.37 -20
TPI c GK c/k/n/u -1.48 ≈ 0.07 ≈ 18.5
TPI c GPO a -1.48 -0.04 -16
GT a PFK k 23 -0.026 -90
GT a PGK k 23 -0.13 -12
HK a PFK c 0.6 -9 -90
Numerical values are the relative flux reductions in   (reference flux: ≈ 90, corresponding to 1.5·10-3  ) resulting from a 
modification at an effective concentration of 100. The abbreviations stand for the targets (glycerol 3 phosphate oxidase (GPO), glycerol kinase 
(GK), phosphofructokinase (PFK), triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK), and hexokinase (HK)) and the modification 
types (competitive (c), noncompetitive (n), uncompetitive (u), competitive for cofactors (k), and activation (a)).
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